These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 33913637

  • 21. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
    Nangaku M, Ueta K, Nishimura K, Sasaki K, Hashimoto T.
    Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
    [Abstract] [Full Text] [Related]

  • 22. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE.
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [Abstract] [Full Text] [Related]

  • 23. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT, Hiremath S, Jun M, Green SC, Wheeler DC, Coyne DW, Perkovic V, Badve SV.
    NEJM Evid; 2024 Sep; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Little DJ, Houser MT, Frison L, Houghton J, Neff TB.
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [Abstract] [Full Text] [Related]

  • 26. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM.
    Am J Nephrol; 2017 Aug; 45(5):380-388. PubMed ID: 28343225
    [Abstract] [Full Text] [Related]

  • 27. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
    Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators.
    N Engl J Med; 2009 Nov 19; 361(21):2019-32. PubMed ID: 19880844
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
    Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T, PREDICT Investigators.
    Clin J Am Soc Nephrol; 2020 May 07; 15(5):608-615. PubMed ID: 32245781
    [Abstract] [Full Text] [Related]

  • 30. Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD.
    Nangaku M, Kondo K, Kokado Y, Ueta K, Kaneko G, Tandai T, Kawaguchi Y, Komatsu Y.
    J Am Soc Nephrol; 2021 Jul 07; 32(7):1779-1790. PubMed ID: 33883252
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials.
    Agarwal R, Anand S, Eckardt KU, Luo W, Parfrey PS, Sarnak MJ, Solinsky CM, Vargo DL, Winkelmayer WC, Chertow GM.
    Am J Nephrol; 2022 Jul 07; 53(10):701-710. PubMed ID: 36450264
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.
    Kidney Int; 2016 Nov 07; 90(5):1115-1122. PubMed ID: 27650732
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J, Sulowicz W, Schömig M, Esposito C, Reusch M, Young J, Csiky B.
    Adv Ther; 2021 Oct 07; 38(10):5345-5360. PubMed ID: 34523074
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
    Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB.
    Clin J Am Soc Nephrol; 2019 Dec 06; 14(12):1701-1710. PubMed ID: 31420350
    [Abstract] [Full Text] [Related]

  • 38. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
    Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I.
    Clin Exp Nephrol; 2018 Feb 06; 22(1):78-84. PubMed ID: 28660446
    [Abstract] [Full Text] [Related]

  • 39. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA, Meyer Reigner S, Tirodkar C, Drozdz D.
    Am J Kidney Dis; 2023 Jun 06; 81(6):684-694.e1. PubMed ID: 36587890
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.